Want to see AU:HPC full AI Analyst Report?
HPC Stock Chart & Stats
AU$0.01
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.01
AU$0.00(0.00%)
Day’s Range― - ―
52-Week Range<AU$0.01 - AU$0.02
Previous CloseN/A
Volume65.65K
Average Volume (3M)1.21M
Market Cap
AU$2.69M
Enterprise ValueAU$0.48
Total Cash (Recent Filing)AU$1.12M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.33
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding537,988,460
10 Day Avg. Volume3,315,133
30 Day Avg. Volume1,207,806
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.91
Price to Sales (P/S)0.51
P/FCF Ratio-0.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageThe reported absence of debt in 2024–2025 materially lowers interest and refinancing pressure, giving the company greater solvency resilience. Over a 2–6 month horizon this preserves optionality to raise capital or restructure without heavy fixed finance costs, aiding stability while cash burn is addressed.
Lean Operating HeadcountAn extremely small headcount implies a low fixed-cost base and operational flexibility; the company can limit incremental payroll-driven burn and outsource functions as needed. Over months this structural lightness helps extend runway and enables management to reallocate scarce capital toward revenue-generating activities.
Stable End-market CategoryOperating in food distribution exposes the company to a structurally steady demand profile because food is essential. Over a medium-term horizon this industry stability supports recovery potential if operations and margins are restored, and provides predictable end-market tailwinds versus cyclical sectors.
Bears Say
Persistent Negative Cash FlowChronic operating cash outflows and a materially larger 2025 cash burn signal the business is not self-funding and depends on external capital. Over 2–6 months this reduces financial flexibility, increases refinancing risk, and limits the firm's ability to invest in growth or stabilize operations without dilutive or costly funding.
Structurally Unprofitable OperationsNegative gross profit and deep operating losses indicate the core business fails to cover direct costs, not just overhead. This structural unprofitability requires either margin recovery or cost restructuring to be sustainable. Without durable improvement, operating deficits will continue to erode capital over the medium term.
Balance-sheet Volatility And Weak EquityHistoric negative equity and material asset contraction point to capital erosion and possible dilution or asset sales to raise cash. Over the coming months this instability constrains strategic options, undermines creditor confidence, and raises the risk the company must seek dilutive financing or execute fire-sale asset transactions.
Hydration Pharmaceuticals Co. Ltd. News
HPC FAQ
What was Hydration Pharmaceuticals Co. Ltd.’s price range in the past 12 months?
Hydration Pharmaceuticals Co. Ltd. lowest share price was <AU$0.01 and its highest was AU$0.02 in the past 12 months.
What is Hydration Pharmaceuticals Co. Ltd.’s market cap?
Hydration Pharmaceuticals Co. Ltd.’s market cap is AU$2.69M.
When is Hydration Pharmaceuticals Co. Ltd.’s upcoming earnings report date?
Hydration Pharmaceuticals Co. Ltd.’s upcoming earnings report date is Aug 28, 2026 which is in 7 days.
How were Hydration Pharmaceuticals Co. Ltd.’s earnings last quarter?
Hydration Pharmaceuticals Co. Ltd. released its earnings results on Feb 27, 2026. The company reported -AU$0.005 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Hydration Pharmaceuticals Co. Ltd. overvalued?
According to Wall Street analysts Hydration Pharmaceuticals Co. Ltd.’s price is currently Overvalued.
Does Hydration Pharmaceuticals Co. Ltd. pay dividends?
Hydration Pharmaceuticals Co. Ltd. does not currently pay dividends.
What is Hydration Pharmaceuticals Co. Ltd.’s EPS estimate?
Hydration Pharmaceuticals Co. Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hydration Pharmaceuticals Co. Ltd. have?
Hydration Pharmaceuticals Co. Ltd. has 537,988,460 shares outstanding.
What happened to Hydration Pharmaceuticals Co. Ltd.’s price movement after its last earnings report?
Hydration Pharmaceuticals Co. Ltd. reported an EPS of -AU$0.005 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Hydration Pharmaceuticals Co. Ltd.?
Currently, no hedge funds are holding shares in AU:HPC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Hydration Pharmaceuticals Co. Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Company Description
Hydration Pharmaceuticals Co. Ltd.
The Hydration Pharmaceuticals Company Limited, established in 2001, provides a diverse portfolio of healthy hydration remedies, offered as liquids, tablets, and powders. Operating from its headquarters in San Diego, California, the company distributes these Hydralyte-branded items through both conventional retail outlets and digital e-commerce platforms across Australia, the United States, and Canada.
Technical Analysis
Australian Dairy Nutritionals Group
―
Bubs Australia Ltd.
―
Nuchev Pty Ltd
―
Nutritional Growth Solutions Ltd.
―
Clover Corporation Limited
―